Elastic Nanovesicles Offer New Path for Ocular Antibiotic Delivery

A comprehensive review published in Discover Pharmaceutical Sciences examines the potential of spanlastics, a class of elastic nanovesicles, to overcome the significant barriers associated with ocular drug delivery. The study, led by researchers including Saruma Sahin and Manoj Kumar Deka, focuses specifically on the formulation of linezolid-loaded spanlastics as a therapeutic strategy for treating antibiotic-resistant eye infections. By analyzing the physicochemical properties and biological interactions of these nanocarriers, the review highlights how spanlastics can enhance the solubility, stability, and penetration of drugs across ocular tissues. This approach addresses the limitations of conventional delivery systems, which often suffer from poor bioavailability and rapid clearance from the eye.

The human eye presents unique anatomical and physiological challenges for pharmaceutical delivery. Traditional topical formulations, such as eye drops, typically achieve less than 5% ocular bioavailability due to rapid drainage through the nasolacrimal duct and the presence of biological barriers like the corneal epithelium and the blood-retinal barrier. These barriers restrict the movement of drugs, particularly hydrophilic molecules, into deeper ocular tissues. Consequently, many patients require frequent dosing to maintain therapeutic levels, which can reduce compliance and increase the risk of systemic side effects. The review identifies these challenges as the primary motivation for developing advanced nanocarrier systems.

Spanlastics are composed of non-ionic surfactants, such as Span 60, and edge activators, like Tween 80. This specific composition imparts high deformability and elasticity to the vesicles, allowing them to squeeze through narrow intercellular junctions in biological membranes. Unlike rigid liposomes, which may be rejected by mucin layers or fail to penetrate effectively, spanlastics can adapt their shape to traverse ocular barriers. The review notes that this elasticity is a key factor in their ability to enhance drug uptake in both the anterior and posterior segments of the eye. The nanoscale size of spanlastics, typically ranging from 50 to 200 nm, further facilitates their diffusion and interaction with target tissues.

Linezolid, an oxazolidinone antibiotic, is a promising candidate for this delivery system due to its efficacy against Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA). The review details that linezolid has a minimum inhibitory concentration (MIC) between 1 and 4 µg/mL against various pathogens and possesses good penetration into corneal, vitreous, and retinal tissues. However, its low water solubility and short half-life necessitate frequent administration to maintain therapeutic levels. By encapsulating linezolid within spanlastics, the formulation aims to improve the drug’s stability and extend its residence time on the ocular surface, thereby reducing the frequency of dosing required for effective treatment.

The mechanism of action for spanlastics involves several distinct processes that enhance drug delivery. First, the surfactants in the vesicle structure can transiently fluidize the lipid bilayers of the corneal epithelium, increasing membrane permeability without causing irreversible damage. Second, the elastic nature of the vesicles allows them to pass through intercellular spaces, facilitating the transport of the encapsulated drug into deeper tissues. Third, spanlastics can form intratissue depots that enable sustained release of the drug over an extended period. This controlled release profile helps maintain therapeutic concentrations in the eye, minimizing the peaks and troughs associated with conventional dosing regimens.

Targeted delivery represents another significant advantage of spanlastic formulations. The review discusses the use of ligand-mediated targeting, where specific molecules are attached to the surface of the spanlastics to bind to receptors overexpressed on diseased tissues. For example, folic acid can be used to target folate receptors in inflammatory tissue, while transferrin can facilitate delivery to the retinal pigment epithelium. This precision targeting ensures that the drug is delivered directly to the site of infection or inflammation, maximizing therapeutic efficacy while minimizing exposure to healthy tissues. Such strategies are particularly relevant for treating posterior segment diseases, where conventional topical administration is often ineffective.

Compared to other nanocarrier systems, spanlastics offer several distinct benefits. They are generally more chemically stable than liposomes, which are prone to fusion and aggregation during storage. The non-ionic surfactants used in spanlastics are biocompatible and biodegradable, reducing the risk of toxicity and immune reactions. Additionally, spanlastics exhibit mucoadhesive properties, which help prolong their retention on the ocular surface. This extended contact time is crucial for ensuring that the drug has sufficient opportunity to penetrate the cornea and reach its target. The review emphasizes that these properties make spanlastics a versatile platform for delivering a wide range of ocular therapeutics, from antibiotics to anti-inflammatory agents.

The review also addresses the technical challenges associated with the production and sterilization of spanlastics. Standard laboratory methods, such as ethanol injection and ultrasonication, are suitable for small-scale preparation but present difficulties when scaled up for industrial manufacturing. Ensuring uniform vesicle size and consistent drug encapsulation efficiency across large batches requires precise control of formulation parameters, including temperature and mixing rates. Sterilization is another critical consideration, as conventional methods like autoclaving can damage the delicate structure of the nanovesicles. The review suggests that sterile filtration through 0.22 μm membranes or aseptic manufacturing processes are preferred methods for producing clinically viable spanlastic formulations.

Regulatory and safety considerations are also discussed in the review. While the individual components of spanlastics, such as Span 60 and Tween 80, are generally recognized as safe (GRAS), the final formulation requires rigorous testing to ensure safety and efficacy. Preclinical studies have shown acceptable cytotoxicity and biocompatibility profiles, but further investigation is needed to establish long-term safety and biodistribution. Regulatory agencies, including the FDA and EMA, are still developing specific guidelines for nanocarrier-based drug delivery systems. The review highlights the need for comprehensive documentation of manufacturing processes and quality attributes to facilitate regulatory approval and clinical translation.

Future research directions for spanlastics in ocular delivery focus on optimizing formulation parameters to enhance penetration into deeper ocular tissues. The review suggests that surface modifications and the incorporation of targeting ligands could further improve the precision of drug delivery. Additionally, the development of combination therapies, where spanlastics co-encapsulate multiple drugs, could address complex ocular conditions that require simultaneous treatment of infection and inflammation. The potential for personalized medicine, where formulations are tailored to individual patient needs, is also noted as a promising area for future exploration. These advancements could lead to more effective and convenient treatments for a wide range of eye diseases.

The review concludes that linezolid-loaded spanlastics represent a promising advancement in ocular drug delivery. By addressing the limitations of conventional systems, these nanocarriers offer the potential to improve therapeutic outcomes for patients with antibiotic-resistant eye infections. The combination of enhanced bioavailability, sustained release, and targeted delivery makes spanlastics a versatile and effective platform for ophthalmic applications. As research continues to refine these formulations and address regulatory challenges, spanlastics may play a significant role in the future of eye care, providing safer and more effective treatment options for patients worldwide.

The review situates linezolid within the broader context of antibiotic resistance, noting that the drug belongs to the oxazolidinone class, a category of antibiotics that primarily targets Gram-positive bacteria. This specificity is crucial because many common ocular infections are caused by resistant strains, such as methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococci (VRE). Linezolid operates by inhibiting bacterial protein synthesis, a mechanism that reduces the likelihood of cross-resistance with other protein synthesis inhibitors. By binding to the 23S region of the 50S ribosomal subunit, the drug prevents the formation of a functional 70S initiation complex, effectively halting bacterial growth. This distinct mode of action makes it a valuable candidate for treating infections that have become unresponsive to standard therapies, particularly in the anterior segment of the eye where topical administration is most feasible.

Despite its therapeutic potential, linezolid presents specific physicochemical challenges that complicate its use in ophthalmic formulations. Classified as a Biopharmaceutical Classification System (BCS) class II drug, linezolid exhibits low aqueous solubility, with a solubility of approximately 3 mg/mL at 25 °C. The drug is a weak base with a pKa value around 1.8, meaning it dissolves more readily in acidic solutions. Its molecular weight is 337.351 g/mol, and it has a logP value of 0.9, indicating a balance between hydrophilic and lipophilic properties. These characteristics, combined with its short half-life, necessitate frequent dosing to maintain therapeutic concentrations. The review highlights that while linezolid penetrates corneal, vitreous, and retinal tissues effectively in animal models, its clinical utility as a topical agent has not been fully evaluated in human subjects, leaving a gap in the understanding of its optimal ocular pharmacokinetics.

The structural design of spanlastics offers a solution to these solubility and stability issues by creating a protective microenvironment for the encapsulated drug. The vesicles are constructed from a non-ionic surfactant, typically Span 60, and an edge activator, such as Tween 80. This composition allows the vesicles to be highly deformable, a property that is critical for navigating the complex biological barriers of the eye. The edge activator reduces the integrity of the lipid bilayer, enhancing the vesicle’s ability to change shape and pass through intercellular spaces. This flexibility allows spanlastics to traverse the corneal epithelium more effectively than rigid nanocarriers, which may be hindered by the mucin layer or rejected by the tissue. The review emphasizes that this structural adaptability is a key differentiator, enabling the delivery of both hydrophilic and lipophilic drugs to deeper ocular tissues.

Furthermore, the review discusses the role of spanlastics in overcoming the dynamic barriers of the eye, such as tear turnover and lymphatic drainage. Traditional eye drops are often cleared rapidly from the ocular surface, limiting their therapeutic window. Spanlastics, however, exhibit mucoadhesive properties that prolong their residence time on the eye. This extended contact allows for a more sustained release of the drug, reducing the frequency of administration and potentially improving patient compliance. The review also notes that spanlastics can inhibit efflux transport proteins, such as P-glycoprotein, which actively pump drugs out of cells. By blocking these efflux mechanisms, spanlastics increase the intracellular accumulation of the drug, thereby enhancing its therapeutic efficacy. This dual action of prolonging surface retention and inhibiting efflux makes spanlastics a promising platform for treating chronic ocular conditions that require consistent drug levels over time.

Subject of Research: Spanlastics ocular delivery: a comprehensive review of formulation and therapeutic potential

Article Title: Spanlastics ocular delivery: a comprehensive review of formulation and therapeutic potential

Article References: Sahin, S., Sarma, S., Das, A., Baishya, B., Das, A. K., & Deka, M. K. (2025). Spanlastics ocular delivery: a comprehensive review of formulation and therapeutic potential. Discover Pharmaceutical Sciences, 1(1), Article 9. https://doi.org/10.1007/s44395-025-00009-1

Image Credits: AI Generated

DOI: 10.1007/s44395-025-00009-1

Keywords: Spanlastics, ocular, delivery, comprehensive, review, formulation, therapeutic, potential, scientific research